FOXM1 and neoplasm: Lastly, we utilized the H1299 cells to establish subcutaneous tumor model and found that FOXM1 inhibitor, RCM-1, could significantly suppress the in vivo growth of tumors derived from the PHF1-deficient cells, as evidenced and compared by tumor volumes (Fig. 6K–L).